International Speakers

Dr. Guillermo E. Umpierrez, USA

Area of Specialty: Endocrinology, Diabetes and Metabolism

Dr. Umpierrez is professor of medicine in the division of endocrinology, metabolism at Emory University School of Medicine, and chief of diabetes and endocrinology at Grady Memorial Hospital

Dr. Umpierrez first joined the Emory University School of Medicine faculty in 1992 – 1997. He returned in 2003 to focus on diabetes and metabolic disorders. Dr. Umpierrez’s research interests include mechanisms for ß-cell dysfunction in minority populations with ketosis-prone type 2 diabetes, the effects of free fatty acids on insulin secretion and hypertension in obese patients, and the inpatient management of insulin in critical and non-critical patients. His research programs at Grady Hospital and Emory University are funded by the National Institutes of Health (NIH), American Diabetes Association (ADA), and American Heart Association (AHA).

 

          

 

 

 

Ralph Anthony DeFronzo, USA

Ralph A. DeFronzo, MD, is Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center and the Deputy Director of the Texas Diabetes Institute, San Antonio, Texas.  Dr. DeFronzo is a graduate of Yale University (BS) and Harvard Medical School (MD) and did his training in Internal Medicine at the Johns Hopkins Hospital.  He completed fellowships in Endocrinology at the National Institutes of Health and Baltimore City Hospitals and in Nephrology at the Hospital of the University of Pennsylvania.  Subsequently, he joined the faculty at the Yale University School of Medicine (1975-88) as an Assistant/Associate Professor.  From 1988 to present Dr. DeFronzo has been Professor of Medicine and Chief of the Diabetes Division at the University of Texas Health Science Center at San Antonio.  He also serves as the Deputy Director of the Texas Diabetes Institute.

Dr George L Bakris, USA

Dr.  Bakris  is  a  tenured  Professor  of  Medicine  and Director  of  the  ASH  Comprehensive  Hypertension Center in the Department of Medicine at the University of Chicago Medicine.

Dr. Bakris has published over 800 peer-reviewed articles and book chapters in the areas of diabetic kidney disease, hypertension and progression of nephropathy. He is the Editor or Co-Editor of 20 books, in the areas of Kidney Disease Progression and Diabetes as well as the new 3rd Edition of Hypertension: A Companion to  Braunwald’s  The  Heart . Additionally, he is an Associate Editor of the International Textbook of Cardiology. He was a member of the NIH National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease (1994). He also served as a special government expert to the Cardio-renal Advisory Board of the FDA and to CMS (1994-2008). He was a co-principal investigator on the NIH Clinical Research training grant for clinical research (K30) (1999-2004). He chaired the first National Kidney Foundation Consensus report on blood pressure and impact on renal disease progression (2000). He  has  also  served  on  many  national  guideline  committees  including:  The  Joint  National  Committee Writing  Groups  VI  &  7  (1997,  2003),  the  JNC  7  executive  committee  (2003),  the  American  Diabetes Association Clinical Practice Guideline Committee (2002-2004), the National Kidney Foundation (K-DOQI) Blood Pressure Guideline committee (2002-2004 & 2013), (K-DOQI) Diabetes Guideline committee (2003-2005  &  2014),  Chair,  ADA  BP  Consensus  Report  (2016)  and  writing  committee  ACC/AHA  Resistant Hypertension Consensus report (2016-2017). Dr. Bakris is the past-president of the American College of Clinical Pharmacology (2000-2002) and the American Society of Hypertension (ASH). He is the current Editor-in-Chief, Am J Nephrology, Editor-in-Chief- Up-to-Date, Nephrology section, Hypertension Section Editor Up-to-Date and Assoc. Ed of Diabetes Care. He serves on more than 18 editorial boards including Nephrology,  Dialysis  &  Transplant,  Hypertension,  J  Hypertension  and  J  American  Soc.  Hypertension. Additionally, he is the Hypertension editor of the Merck Manuel.

 

 

 

 

 

Prof Vivian A. Fonseca, USA

Tullis–Tulane Alumni Chair in Diabetes
Professor of Medicine&Chief, Section of Endocrinology

Dr. Fonseca serves on the clinical practice committee of the American Diabetes Association (current chairman) and the joint ADA/ACC “Make the Link” Program. He is the President of Medicine & Science for the American Diabetes Association

He is editor-in-chief of Diabetes Care since 2007, having formerly been associate editor. He was until 2006 editor-in-chief of the Journal of the Metabolic Syndrome and related disorders. He served on the editorial board of the Journal of Clinical Endocrinology and Metabolism (2003-2006). He is an ad hoc reviewer for several other journals including New England Journal of Medicine,JAMA, Diabetes, Diabetic Medicine, Kidney International, the American Journal of Clinical Nutrition, the British Medical Journal, and Metabolism.

Dr. Fonseca is a fellow of the American Association of Clinical Endocrinologists, the Royal College of Physicians (London), and the American College of Physicians. He is a member of the Endocrine Society, the American Diabetes Association, and the International Diabetes Federation. He serves on several national and international committees, and has published over 200 papers, review articles and book chapters.

Research Interests

Dr. Fonseca’s current research interests include the prevention and treatment of diabetic complications and risk factor reduction in cardiovascular disease. He has a research program evaluating homocysteine and inflammation as risk factors for heart disease in diabetes. He is currently the principal investigator of the DRMS (diabetes remote management system) study, a study aimed at evaluating the effectiveness and possibilities of using a remote technology system to enhance and manage daily care for patients with Type 2 Diabetes Mellitus. Dr. Fonseca is also the principal investigator of the Zemplar study, a study investigating the effects of Zemplar (paricalcitol) on endothelial function and inflammation in patients with Type 2 Diabetes Mellitus and stage 3 or 4 chronic kidney disease.

He is also the principal investigator of the ACCORDION study, an NIH sponsored, multicenter follow –up study to the ACCORD study which examined cardiovascular risk and diabetes. Dr. Fonseca is also the principal investigator for the BEACON study, a multicenter study evaluating the effects of bardoxolone methyl in patients with chronic kidney disease and Type 2 diabetes. Dr. Fonseca has lectured in the United States and abroad, and his publications include more than 180 articles. He is the editor of the text book “Clinical Diabetes: Translating Research into Practice” (El Sevier 2006) and several monographs and book chapters.

 

 

 

 

 

 

Dr Sunder Mudaliar, USA

Dr Mudaliar has focused his research in the clinical aspects of type 2 diabetes, especially focusing on novel agents for its prevention and treatment. He has been the Principal Investigator (PI) on over 20 projects at our center, including ACTOS NOW, a major study in the prevention of diabetes. Currently, he is the PI on several industry sponsored grants, evaluating newer medications for the treatment of type 2 diabetes. He is also a Co-investigator in the NIH/NIDDK sponsored multicenter Diabetes Prevention Program Outcome Study, “DPPOS”. This study is a continuation of the earlier landmark diabetes study that showed the intensive lifestyle modification with diet/exercise or intervention with metformin significantly decreased the incidence of diabetes in patients with pre-diabetes. Another NIH funded study on which I am a Co-Investigator is a study evaluating, “Metabolic Effects of Newer Antipsychotics in Older Patients.”

In addition to his research, Dr Mudaliar is a Clinical Professor of Medicine, at the University of California. He is active in the Ambulatory Care component of the University Med 401 Clerkship Program where students rotate through the VA hospital primary care/diabetes clinic. During his inpatient months as Endocrine Consult Attending (2 months) and Medicine Ward Attending (1 month), he teaches students, residents and fellows. He is also involved annually in the OSCE (Objective Structured Clinical Examination) for second year medical students and gives regular lectures/presents cases in the didactic seminar component of Med 401 course on diabetes.

Dr Mudaliar has also been a member of the UCSD Human Research Protections Program since 2002. He is a Board-certified Physician and Endocrinologist and works as a clinician within the VA Medical Center Primary Care and Diabetes Care Clinic, Lipid Clinic, General Medicine, Endocrine Consult Service, and the Inpatient Diabetes Consult Service.